Showing results (271-280 of 317) with videos related to

Sort By:
Pageof 32
ESMO Open|February 22, 2025
Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2S Stintzing, J Tabernero, T Satoh, et al.
Iscience|November 20, 2024
Sea level rise and the evolution of aggression on islandsKenneth F Rijsdijk, Jasper C Croll, Julian P Hume, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2020
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 studyE Van Cutsem, I Danielewicz, M P Saunders, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER)M Moehler, A Maderer, P C Thuss-Patience, et al.
ESMO Open|February 13, 2026
NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trialT Macarulla, R Pazo Cid, M S Womack, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2007
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015C-H Köhne, J De Greve, J T Hartmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 30, 2016
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patientsJ Taieb, R Balogoun, K Le Malicot, et al.
ESMO Open|August 5, 2025
Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trialD Melisi, T Macarulla, C De La Fouchardière, et al.
ESMO Open|June 5, 2024
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202A Vogel, V Sahai, A Hollebecque, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 29, 2019
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparibP Hammel, H L Kindler, M Reni, et al.
Pageof 32